{"id":692283,"date":"2022-10-05T08:03:25","date_gmt":"2022-10-05T12:03:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"modified":"2022-10-05T08:03:25","modified_gmt":"2022-10-05T12:03:25","slug":"adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","title":{"rendered":"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"},"content":{"rendered":"

<\/p>\n

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) <\/b>37th<\/sup> Annual Meeting<\/b><\/p>\n

\nAdicet to Host R&D Webcast Event on Thursday, November 10, 2022 at 9:00am EST\n<\/p>\n

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE<\/a>)–
\nAdicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th<\/sup> Annual Meeting taking place November 8-12, 2022 in Boston, MA.\n<\/p>\n

Poster Presentations:<\/b><\/p>\n

Abstract Title<\/b>: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of \u03b3\u03b4 T Cell Immunotherapy
\n
Poster\/Abstract Number<\/b>: 198
\n
Presenting Author<\/b>: Marissa Herrman, Ph.D.
\n
Date<\/b>\/Time<\/b>: November 11, 2022 from 9:00am \u2013 9:00pm EST\n<\/p>\n

Title<\/b>: Preclinical Discovery and Characterization of Allogeneic anti-PSMA \u03b3\u03b4 CAR T Therapy for Prostate Cancer
\n
Poster\/Abstract Number<\/b>: 203
\n
Presenting Author<\/b>: Nitya S. Ramadoss, Ph.D.
\n
Date<\/b>\/Time<\/b>: November 10, 2022 from 9:00am \u2013 9:00pm EST\n<\/p>\n

Abstract Title<\/b>: Allogeneic \u201coff-the-shelf\u201d \u03b3\u03b4 T cells modified with CD27- containing CAR for targeting CD70+ cancers
\n
Poster\/Abstract Number<\/b>: 246
\n
Presenting Author<\/b>: Kevin P. Nishimoto, Ph.D.
\n
Date<\/b>\/Time<\/b>: November 11, 2022 from 9:00am \u2013 9:00pm EST\n<\/p>\n

Abstract Title<\/b>: Preclinical Discovery and Evaluation of Allogeneic \u201coff-the-shelf\u201d \u03b3\u03b4 CAR T Cells Targeting B7-H6+ Tumors
\n
Poster\/Abstract Number<\/b>: 247
\n
Presenting Author<\/b>: Kevin P. Nishimoto, Ph.D.
\n
Date<\/b>\/Time<\/b>: November 10, 2022 from 9:00am \u2013 9:00pm EST\n<\/p>\n

\nThe abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC)<\/a><\/i> supplement, which will be published on Monday, November 7 at 8:00am EST on www.sitcancer.org<\/a>.\n<\/p>\n

R&D Webcast<\/b><\/p>\n

\nAdicet will host an R&D webcast presentation on Thursday, November 10, 2022 at 9:00am EST to provide an overview of its R&D pipeline.\n<\/p>\n

About Adicet Bio, Inc.<\/b><\/p>\n

\nAdicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies engineered to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http:\/\/www.adicetbio.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20221005005195\/en\/<\/a><\/span><\/p>\n

Adicet Bio., Inc.
\n<\/b>
Investor and Media Contacts<\/b><\/p>\n

\nAnne Bowdidge
\n
abowdidge@adicetbio.com<\/a><\/p>\n

\nJanhavi Mohite
\n
Stern Investor Relations, Inc.
\n
212-362-1200
\n
janhavi.mohite@sternir.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Adicet to Host R&D Webcast Event on Thursday, November 10, 2022 at 9:00am EST REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)– Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA. Poster Presentations: Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of \u03b3\u03b4 T Cell Immunotherapy … <\/p>\n

Continue reading “Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692283","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Adicet to Host R&D Webcast Event on Thursday, November 10, 2022 at 9:00am EST REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)– Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA. Poster Presentations: Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of \u03b3\u03b4 T Cell Immunotherapy … Continue reading "Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T12:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\",\"datePublished\":\"2022-10-05T12:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"},\"wordCount\":427,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\",\"name\":\"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2022-10-05T12:03:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk","og_description":"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Adicet to Host R&D Webcast Event on Thursday, November 10, 2022 at 9:00am EST REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)– Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA. Poster Presentations: Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of \u03b3\u03b4 T Cell Immunotherapy … Continue reading \"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T12:03:25+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","datePublished":"2022-10-05T12:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"wordCount":427,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","name":"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en","datePublished":"2022-10-05T12:03:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221005005195r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adicet-bio-to-present-preclinical-data-from-allogeneic-gamma-delta-t-cell-pipeline-programs-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692283"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692283\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}